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Antimicrobial Stewardship Barriers and
Goals in Pediatric Oncology and Bone
Marrow Transplantation: A Survey of
Antimicrobial Stewardship Practitioners
Joshua Wolf, MBBS, FRACP;1,2 Yilun Sun, MS;3 Li Tang,
PhD;3 Jason G. Newland, MD, MEd;4 Jeffrey S. Gerber, MD,
PhD;5 Christie J. Van Dyke, PharmD, BCPS;6 Saul R. Hymes,
MD;7 Diana Yu, PharmD, BCPS;8 Delia C. Carias, PharmD,
BCPS;9 Penelope A. Bryant, MBBS, PhD, FRACP10 on behalf
of the Pediatric Hematology/Oncology Antimicrobial
Stewardship Interest Group

We undertook a cross-sectional survey of antimicrobial stewardship
clinicians in North America and Australasia regarding practices, goals,
and barriers to implementation of stewardship for pediatric oncology
patients. Goals and barriers were similar regardless of clinician or
institutional characteristics and geographic location. Strategies
addressing these factors could help optimize antimicrobial use.
Infect. Control Hosp. Epidemiol. 2 01 6; 3 7( 3) :3 4 3– 3 47

Children undergoing cancer therapy or bone marrow transplantation (BMT) are at high risk of serious infection and
receive frequent, prolonged courses of broad-spectrum antimicrobial agents.1,2 Although some antimicrobial exposure is
appropriate, usage in many cases is inconsistent with evidencebased guidelines and results in signiﬁcant toxicity, resistance,
antibiotic-associated infections, and ﬁnancial cost.3–6 Many
institutions have attempted to optimize antimicrobial
prescribing by implementing antimicrobial stewardship
programs (ASPs).7,8 However, little is known about the main
antimicrobial stewardship goals, current interventions, or
barriers to those interventions in this group. Proposed barriers
include insufﬁcient time-allocation or expertise; patient complexity; and perceptions or attitudes of oncology physicians1,2,9
but these have not been examined in pediatric oncology. We
addressed this knowledge gap by conducting a survey assessing
the goals and perceived barriers for ASP clinicians practicing in
pediatric hematology and oncology.

m e th o d s
A focus group at the annual Pediatric Infectious Diseases
Society Antimicrobial Stewardship Conference was asked to
identify goals for, and barriers to, antimicrobial stewardship in
pediatric oncology or BMT patients. These were combined
with published information1,2,9 to create an online survey

exploring goals and barriers to antimicrobial stewardship
(Supplementary Figure 1).
Antimicrobial stewardship and infectious diseases clinicians
were contacted by email and invited to participate in the survey
(SurveyMonkey). Email addresses were collated from 2
mailing lists (pediatric infectious diseases listservs from North
America and Australasia), attendees at the Pediatric Infectious
Diseases Society Antimicrobial Stewardship Conference, and
other relevant clinicians. Data were collected from July 30
through August 25, 2014.
After we excluded duplicate responses, data were deidentiﬁed. Responses from clinical pharmacists or infectious diseases
clinicians working in institutions that care for pediatric
oncology patients were included. Oncology, malignant
hematology, and BMT are grouped as “oncology” for this
report. Respondent or institutional characteristics were
described as a proportion of all included responses for each
question. Stepwise multiple logistic regression was used to
determine associations between respondent characteristics and
barriers or goals. Barriers were dichotomized, with responses
of “quite important,” “very important,” and “important”
regarded as important, and responses of “not at all important,”
“not very important,” or “somewhat important” regarded as
not important. For geographic associations, responses from the
United States, Mexico, and Canada were regarded as a single
group, as were those from Australia and New Zealand. These
analyses were performed with SAS, version 9.3 (SAS Institute),
and unadjusted P values less than .05 were considered
signiﬁcant. Clustering analysis for reported barriers was
performed by visual inspection of an unsupervised hierarchical
clustering dendrogram (Spotﬁre Decision Site; TIBCO).
The project was approved by the institutional review board
of St. Jude Children’s Research Hospital, and all participant
data were deidentiﬁed before analysis. Respondents, except for
the 10 named authors, were eligible to win a prize valued at
$50. Participants were given an opportunity to opt out of the
study prior to deidentiﬁcation.

resul ts
The survey link was sent to 149 recipients in North America
and 123 in Australasia; 102 responses were received. Of the 102
responses, 5 were excluded (3 ineligible type and 2 worked in
institutions without pediatric oncology patients). The
remaining cohort of 97 included 18 from Australasia, 72 from
North America, and 7 who did not report a geographic
location or institutional afﬁliation. The analysis cohort
comprised 55 infectious diseases physicians, 13 fellows, and
29 clinical pharmacists; 65 respondents (67%) reported that
stewardship was at least 10% of their work effort. Participants
represented at least 45 institutions in the United States,
Australia, New Zealand, Mexico, and Canada. Respondents
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Antimicrobial Stewardship Goals in Pediatric Oncology From 97 Respondents

Goal

na

(%)

Respondents more likely to report goal

Reduce time to antimicrobial de-escalation
Avoid initiation of unnecessary antibiotics
Reduce redundant coverage
Guideline development
Clinician education
Reduce time to appropriate therapy for resistant infection
Prevent adverse effects
Reduce antimicrobial costs
Promote switch from IV to oral antibiotics

72
60
51
36
28
18
13
7
4

(74)
(62)
(53)
(37)
(29)
(19)
(13)
(7)
(4)

Australasian (OR, 4.2 [95% CI, 1.1–15.7])

ASP work effort <10% (OR, 3.5 [95% CI, 1.1–10.6])

NOTE. ASP, antimicrobial stewardship program; ASP work effort, proportion of work effort dedicated to antimicrobial stewardship; IV, intravenous; OR, odds ratio.
a
n = number of respondents reporting this as one of their top 3 antimicrobial stewardship goals in pediatric oncology.

from 41 of the 45 institutions reported having a formal ASP,
with 15 of the 41 (37%) reporting the program had been active
for at least 3 years. Twenty-four of the 41 centers (59%) had at
least 0.5 full-time equivalent personnel assigned to antimicrobial stewardship.
All respondents from hospitals with formal ASPs reported
they undertake stewardship activities in the pediatric oncology
patient population (median number of activities, 6).
Commonly reported activities in pediatric oncology included
clinical guideline development (36 [80% of 45 institutions]),
dose optimization (35 [78%]), resistance monitoring
(34 [76%]), prospective audit with feedback (32 [71%]),
monitoring of cultures (30 [67%]), clinician education
(29 [64%]), and encouraging oral switch (28 [62%]). Other
reported interventions included audit with delayed feedback
(13 [29%]) and antibiotic cycling (4 [9%]).
Respondents’ reports of their top 3 antimicrobial stewardship goals for the pediatric oncology patient population are
shown in Table 1. Overall, 90 (93%) of 97 respondents
reported either reducing time to de-escalation or avoiding
initiation of unnecessary antibiotics as a priority. Only 2 goals,
reducing time to effective therapy for resistant infection and
preventing adverse effects of antimicrobials, were found to be
correlated with respondent or institutional characteristics.
Reported barriers to effective stewardship in pediatric
oncology patients are show in Table 2. Additional reported
barriers were inconsistency or conﬂict within the infectious
diseases or ASP team (n = 5) and lack of electronic prescribing
(n = 2). Sixty-seven clinicians (69%) reported that inclusion of
antimicrobial guidelines in internally or externally derived
treatment pathways, such as clinical practice guidelines or
collaborative group clinical trial protocols, was an important
barrier to stewardship. Participants devoting at least 10% of
their time to stewardship were more likely than others to
report several barriers as important, but most barriers were
otherwise not signiﬁcantly associated with respondent or
institutional characteristics. On clustering analysis, 4 main
groups of related barriers were evident: (1) ASP lack of interest

or expertise in pediatric oncology; (2) lack of communication,
trust, or shared beliefs between ASP and oncology clinicians;
(3) lack of ASP resources (data analysis or clinician time); and
(4) oncology clinicians’ reliance on current strategies or fear of
rare adverse outcomes (Supplementary Figure 2).

d is c u s s i o n
This report explores the experiences of antimicrobial
stewardship clinicians as they try to optimize antimicrobial use
in pediatric oncology and BMT patients. We aimed to describe
current stewardship activities and to identify the goals and
barriers experienced by antimicrobial stewardship clinicians
working in this ﬁeld and determine whether these were linked
to clinician or institutional characteristics.
We found that stewardship clinicians are actively working to
improve antimicrobial use in the treatment of pediatric
oncology and BMT patients in North America and Australasia.
Despite signiﬁcant differences between practitioners and
institutions, these clinicians report very similar goals and
strategies; most prioritize the goals of reduced initiation or
expedited cessation of unnecessary antimicrobials, and most
use the commonly recommended approaches of guideline
development, prospective audit with feedback, clinician
education, and formulary restriction to achieve those
goals.1,2,7–9 Barriers to effective stewardship are also strikingly
homogeneous, with resource limitations and differences in risk
perception or motivation between the ASP and the oncology
teams appearing most frequently.
Use of audit with delayed feedback is an unexpected ﬁnding.
This differs from the usual method of prospective audit by
delivering feedback in batches (eg, a monthly summary of
antimicrobial usage by individual clinicians or units). In contrast to prospective audit, it is not well described outside of the
ambulatory setting. It may be less resource intensive and
should be further explored.
Reported stewardship goals may be important for determining
ways to assist ASP efforts or conducting collaborative research

stewardship in pediatric oncology

table 2.
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Barriers to Antimicrobial Stewardship in Pediatric Oncology From 97 Respondents
Any

Important

Reported barrier

n

(%)

n

(%)

Respondents more likely to report barrier

Barriers related to the antimicrobial stewardship program
1. Insufﬁcient data analysis resources

81

(84)

51

(53)

ASP work effort ≥10%
(OR, 3.2 [95% CI, 1.2–8.3])

2. Insufﬁcient clinician time assigned to antimicrobial stewardship
3. ASP does not have enough power or authority

77
67

(79)
(69)

50
45

(52)
(46)

4. Not enough communication with oncology clinicians
5. ASP does not have enough expertise in managing infections in
immunocompromised hosts
6. ASP believes that other populations have higher priority
Barriers related to oncology clinicians
1. Oncology clinicians are more motivated by fear of rare adverse
outcomes than long-term risks of antimicrobial use
2. Oncology clinicians are conﬁdent in their antibiotic
knowledge or current antimicrobial strategies
3. Oncology clinicians are not motivated by reducing
ﬁnancial costs (eg, use of expensive antibiotics)
4. Oncology clinicians are concerned about loss of autonomy
5. Oncology clinicians do not believe that their
antimicrobial use leads to antimicrobial resistance
6. Oncology clinicians don't show conﬁdence in ASP/ID clinicians

47
18

(48)
(19)

21
5

(22)
(5)

10

(10)

3

(3)

86

(89)

72

(74)

84

(87)

50

(52)

71

(73)

53

(55)

66
64

(68)
(66)

42
42

(43)
(43)

54

(56)

24

(25)

N/A

46

(47)

N/A

41

(42)

Barriers related to infection treatment protocols
1. Oncology clinicians follow externally derived
collaborative group protocols
2. Insufﬁcient ID or ASP input into local clinical practice guidelines

ASP work effort ≥10%
(OR, 2.9 [95% CI, 1.1–7.6])

Clinical pharmacist
(OR, 4.6 [95% CI, 1.8–11.6])
ASP work effort ≥10%
(OR, 12.2 [95% CI, 1.5–97])

NOTE. Any, barrier reported as at least “somewhat important”; ASP, antimicrobial stewardship program; ASP work effort, proportion of work
effort dedicated to antimicrobial stewardship; ID, infectious diseases; Important, barrier reported as “quite important,” “important,” or “very
important”; N/A, not available; OR, odds ratio.

and quality-improvement programs. Because many goals were
shared by most respondents, effective strategies addressing these
might help improve stewardship at most institutions.
Only 2 goals were signiﬁcantly correlated with clinician or
institution characteristics. Australasian clinicians appear to
view prevention of adverse effects as more central to their role
than those in North America, perhaps because of local cultural
expectations. Similarly, clinicians spending more time
attending to stewardship apparently focus on reducing overall
antibiotic use, leading to a surprising inverse association
between ASP work effort and the goal of decreasing time to
effective therapy in resistant infections. Future studies could
explore the extent to which the proportion of work effort
clinicians dedicate to stewardship and local cultural expectations inﬂuence decision-making within ASPs or affect ASP
effectiveness in other settings.
The study also identiﬁed important barriers faced by
stewardship clinicians in the pediatric oncology population.
Reported barriers clustered tightly according to identiﬁable
themes. The importance of understanding and addressing
barriers to stewardship implementation is supported by evidence that adherence to ASP recommendations in the

treatment of patients with cancer can be relatively poor and
that adherence improves patient outcomes.6,10 Future prospective collaborative research that focuses on addressing these
barriers is likely to be attractive to ASP clinicians and could
identify ways to improve important institutional and patient
outcomes. Previous publications have listed possible
challenges to effective ASP in this population,1,2,9 but to our
knowledge this study is the ﬁrst to investigate the relative
importance of speciﬁc barriers to ASP clinicians.
Many clinicians reported that collaborative group treatment
protocols interfere with stewardship. This could be addressed
by ensuring that oncology research protocols allow ﬂexibility
for stewardship, provide evidence for antimicrobial recommendations, or include research aims to help support future
recommendations. Indeed, these networks might provide
opportunities for stewardship or quality-improvement projects.
The formal response rate for the survey was relatively low
(38%) and was higher in North America (~50%) than
Australasia (~17%). However, it should be noted that the
survey link was distributed to a large group to maximize the
number of eligible participants, and that the listservs used to
contact potential recipients include both adult clinicians and
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pediatric clinicians not involved in antimicrobial stewardship.
Some recipients were therefore ineligible to complete the survey
and, if identiﬁable, would not be included in the denominator
for calculation of the formal response rate. Conversely, because
the survey was distributed by email, recipients could pass the
link to other clinicians. The number of evaluable responses
from Australasia was small (n = 18) but is proportional to the
size of the clinician and patient population in that region (where
there are only 8 free-standing pediatric hospitals).
Additionally, the data were analyzed at the level of the
individual respondent, and some institutions were represented
by multiple respondents; respondent institution was not
included in the regression analysis because the number of
institutions was large compared with the sample size. Similarly, grouping different countries by geographic region may
mask differences between those countries. Infectious diseases
fellows were grouped with attending physicians because their
responses to all survey components were similar, but this may
not be appropriate in other studies. Lastly, the study describes
the perceptions of antimicrobial stewardship clinicians, rather
than objective facts about beliefs or behavior of others.
Antimicrobial stewardship clinicians are actively working to
optimize antimicrobial use in the pediatric oncology patient
population. Regardless of individual or institutional characteristics and geographic boundaries, ASP clinicians report similar
goals and strategies. Important barriers to stewardship in this
setting include personnel and data-analysis limitations,
challenging relationships, and differences in priorities and risk
assessment between stewardship and oncology clinicians.
Further research and quality improvement efforts directed
towards these shared goals and barriers may help improve
antimicrobial use in this uniquely vulnerable population.
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